Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Are structural characteristics of programs and hospitals associated with 100-day readmission of hematopoietic SCTs in Taiwan?

Bone Marrow Transplantation volume 46, pages 1203–1209 (2011)Cite this article

Subjects

Abstract

Hematopoietic SCT (HSCT) is one treatment modality for hematological malignancies. It is increasingly common but remains centralized in certain hospitals wherein procedures and protocols can vary. This study examined 100-day readmission for patients with hematological malignancies undergoing HSCT in Taiwan from the years 2001 to 2006. Of particular interest was an examination of how HSCT program characteristics might influence outcomes. This population-based retrospective cohort study with longitudinal follow-up used Taiwan's National Health Insurance Research Database. A generalized linear model with a logistic-dependent variable representing being admitted or not admitted was used to model 100-day readmission, adjusting for the nested design. There were 718 HSCT recipients for hematological malignancies in the 5-year study period from 10 HSCT programs. In spite of the average length of stay of 43.71 days (s.d.=25.75) days, 52% of recipients were readmitted within 100 days of discharge. Ownership status, the number of HSCT hematologists, and the ratio of HSCT procedures to HSCT hematologists independently predicted 100-day readmission after adjusting for clustered data and controlling for recipient characteristics.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Pasquini M, Wang Z, Schneider L . Current use and outcome of hematopoietic stem cell transplantation: part I–CIBMTR summary slides, 2007. CIBMTR Newsletter 2007; 13: 5–9. Available from http://www.cibmtr.org/ReferenceCenter/Newsletters/Pages/index.aspx (Accessed 25 May 2008).

    Google Scholar 

  2. Jones JA, Qazilbash MH, Shih Y-C, Cantor SB, Cooksley CD, Elting LS . In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies. Cancer 2008; 112: 1096–1105.

    Article  PubMed  Google Scholar 

  3. Saito AM, Cutler C, Zabrieh D, Soiffer RF, Ho VT, Alyea EP et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant 2008; 14: 197–207.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Mitchell PH, Ferketich S, Jennings BM . Quality health outcomes model. Image J Nurs Scholarship 1998; 30: 43–46.

    Article  CAS  Google Scholar 

  5. Andersen R, Rice T, Kominski G . Changing the US Health Care System. Jossey-Bass: San Francisco, CA, 1996.

    Google Scholar 

  6. Grant M, Cooke L, Bhatia S, Forman SJ . Discharge and unscheduled readmissions of adult patients undergoing hematopoietic stem cell transplantation: implications for developing nursing intervention. Oncol Nurs Forum 2005; 32: E1–E8.

    Article  PubMed  Google Scholar 

  7. Moya R, Espigado I, Parody R, Carmona M, Marquez F, De Blas JM . Evaluation of readmission in hematopoietic stem cell transplant recipients. Transplant Proc 2006; 38: 2591–2592.

    Article  CAS  PubMed  Google Scholar 

  8. National Health Research Institute. National Health Insurance Research Database. 2003. 2008. Available from http://www.nhri.org.tw (Accessed 1 October 2008).

  9. UCLA Academic Technology Services. (n.d.). Statistical computing seminars: survival analysis with SAS. Available from http://www.ats.ucla.edu/stat/sas/seminars/sas_survival/default.htm (Accessed 28 April 2009).

  10. Iezzoni LI . Risk Adjustment for Measuring Healthcare Outcomes 3rd edn. Health Administration Press: Chicago, IL, 2003.

    Google Scholar 

  11. Farsi M . Changes in hospital quality after conversion in ownership status. Int J Health Care Finance Eco 2004; 4: 211–230.

    Article  Google Scholar 

  12. Taiwan Joint Commission on Hospital Accreditation. Quality improvement is shown on. http://www.tjcha.org.tw/quality.asp?catid=5 (Accessed on 31 May 2009)..

  13. Loberiza FR, Zhang M-J, Lee SJ, Klein JP, LeMaistre CF, Serna DS et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood 2005; 105: 2979–2987.

    Article  CAS  PubMed  Google Scholar 

  14. Georgy M, Yonescu R, Griffin CA, Batista DA . Acute mixed lineage leukemia and a t(6;14)(q25;q32) in two adults. Cancer Genet Cytogenet 2008; 185: 28–31.

    Article  CAS  PubMed  Google Scholar 

  15. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R . Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006; 108: 1421–1423.

    Article  CAS  PubMed  Google Scholar 

  16. Lee K-H, Lee J-H, Choi S-J, Lee J-H, Kim S, Seol M et al. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant 2003; 32: 835–842.

    Article  CAS  Google Scholar 

  17. Rowley JD . Seminars from the University of Minnesota. Chromosome translocations: dangerous liaisons. J Lab Clin Med 1998; 132: 244–250.

    Article  CAS  PubMed  Google Scholar 

  18. Wang Y, Wu D, Sun A, Jin Z, Qiu H, Miao M et al. Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis. Int J Hematol 2008; 87: 167–171.

    Article  CAS  PubMed  Google Scholar 

  19. Labonte L, Iqbal T, Zaidi MA, McDiarmid SA, Huebsch LB, Tay J et al. Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008; 14: 1039–1044.

    Article  PubMed  Google Scholar 

  20. Taiwan Medical Record Management Association. The origin of the association. 2005. Available from http://www.tmra.org.tw/guide.asp?Source=source&item=1 (Accessed 9 May 2009).

  21. Healthcare Cost and Utilization project (HCUP). HCUP comorbidity software version 3.3. 2008, April. Available from http://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp#download (Accessed 2 October 2008).

Download references

Acknowledgements

The authors appreciate dissertation committees of Drs Erika Friedmann, Jeanne Geiger-Brown and Lyn Murphy as well as NHIRD database mentors of Drs Chung-Yi Li and Yu-Tung Huang.

Author information

Authors and Affiliations

  1. Nursing Department, Chang Gung Institute of Technology, Taoyuan, Taiwan

    S-I Hsieh

  2. School of Nursing, University of Maryland at Baltimore, Baltimore, MD, USA

    M Johantgen

  3. National Taipei University of Nursing and Health Science, Graduate Institute of Health Allied Education, Taipei, Taiwan

    L-L Hsu

  4. Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan

    M-C Kuo

  5. College of Medicine, Institute of Gerontology, National Cheng Kung University, Tainan, Taiwan

    T-H Lu

Authors
  1. S-I Hsieh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Johantgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L-L Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M-C Kuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T-H Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S-I Hsieh.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hsieh, SI., Johantgen, M., Hsu, LL. et al. Are structural characteristics of programs and hospitals associated with 100-day readmission of hematopoietic SCTs in Taiwan?. Bone Marrow Transplant 46, 1203–1209 (2011). https://doi.org/10.1038/bmt.2010.282

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.282

Keywords

This article is cited by

Search

Advanced search

Quick links